SOUNDTRACK-B: This study is recruiting people with relapsed or refractory B-cell Non-Hodgkin Lymphoma who have had at least two prior lines of treatment to evaluate how safe and effective a new intravenous (IV) medicine isA Modular Phase 2, Single-arm, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of AZD0486 in Participants With Relapsed or Refractory (R/R) B-cell Non-Hodgkin Lymphoma (SOUNDTRACK-B)

Inclusion

1. Aged 18 years old and above
2. Histologically confirmed relapsed refractory FL (Module 1) and LBCL (Module 2) after at least 2 prior lines of therapy
3. ECOG performance status 0 to 2
4. Locally confirmed CD-19 expression in lymphoma cells after progression from last CD 19 directed therapy
5. FDG-avid disease with at least one bi-dimensionally measurable nodal lesion (defined as > 1.5 cm in its longest dimension), or extranodal lesion (defined as > 1.0 cm in its longest dimension)

6. Adequate hematological function: ANC ≥ 1000/mm3, platelets

   • 75,000/mm3, hemoglobin ≥ 9 g/dL. Transfusion and/or growth factor are allowed but counts must be stable for at least 72 hours afterwards prior to screening
7. Adequate liver function: total bilirubin <1.5x ULN, AST/ALT ≤ 3xULN or < 5 × ULN in the presence of lymphoma involvement of the liver
8. Adequate renal function: creatinine clearance (CrCl) of ≥ 45 mL/min
9. Adequate cardiac function, defined as left ventricular ejection fraction (LVEF) ≥ 45% by echocardiogram or MUGA

The above is a summary, other inclusion criteria details may apply.